1. Introduction {#sec0005}
===============

Cannabis is the second most used drug after alcohol, with 22.9% of high school seniors and 20% of college students using in the past month, and perhaps most alarmingly, one in every 15 seniors reporting daily use ([@bib0220]). Cannabis legislation changes are sweeping across the United States. Policy experts predict that increased access and reduced price will lead to increased usage, especially in young adults who are the heaviest users ([@bib0065]). Late adolescence and emerging adulthood is a period of ongoing neurodevelopment, with pruning of inefficient gray matter connections ([@bib0130], [@bib0135]). Healthy adult rats demonstrate enhanced binding of cannabinoid (CB~1~) receptors within areas such as the prefrontal cortex (PFC) ([@bib0465]) in comparison to juveniles, suggesting increased reliance upon the cannabinoid system with age. Indeed, converging lines of animal and human evidence have suggested that this is a sensitive period that may be particularly vulnerable to cannabis-induced neurocognitive effects ([@bib0205], [@bib0315]; see [@bib0240] for review).

Preclinical animal models suggest that endogenous endocannabinoid signaling in the PFC influences executive functioning (EF) performance (for review see [@bib0105]). In humans, significant CB~1~ receptor density has been measured in the PFC, a region associated with mood regulation and EF, and throughout the cortex ([@bib0140], [@bib0425]; see [@bib0505]). Therefore, disruption of the endogenous cannabinoid system during adolescence may particularly impact the integrity later developing regions, such as the PFC and parietal lobes ([@bib0130], [@bib0135]). Indeed, daily cannabis users demonstrate significant, though reversible, downregulation of the CB~1~ density in PFC and other cortical regions including the parietal lobes ([@bib0190]). Further, cannabis-using youth demonstrate impairments in executive functioning, including complex attention, inhibitory control, and working memory ([@bib0175], [@bib0170], [@bib0300], [@bib0245]).

Previous structural magnetic resonance imaging (MRI) research has demonstrated that regular (weekly or more) cannabis using adolescents demonstrate larger PFC (including orbitofrontal cortex) volume in female cannabis users ([@bib0310]) and reduced medial orbitofrontal volumes in a primarily male sample ([@bib0075]). Our group has found reduced medial orbitofrontal (mOFC) and inferior parietal volumes in this same sample of young adults ([@bib0350]) compared to controls, and other groups have found that earlier age of onset significantly predicted decreased right superior PFC thickness ([@bib0265]). Recent MRI advances have yielded new measurements of cortical architecture that may be more sensitive to drug effects than volume or cortical thickness. One such candidate is local gyrification index, or a 3-dimensional ratio representing the degree of folding on the outer surface relative to buried cortex within neighboring sulci, which may also be calculated for regions of interest ([@bib0380], [@bib0375]). Several candidate theories attempt to explain the primary driving mechanisms of gyrification development, including cortico-cortical mechanical tension, morphogenetic, and differential cortical expansion rate influences ([@bib0360]; see [@bib0455], [@bib0435], [@bib0365], [@bib0420]; see [@bib0235], [@bib0185], [@bib0485] for reviews). Another measure is cortical surface area (SA), which is a reflection of the amount of area on the cortical surface represented in mm^2^ ([@bib0085]).

Age-related changes in cortical surface area (SA) and other surface characteristics, including gyral and sulcal shape, have been noted in several preliminary studies. [@bib0385] measured SA changes between MRI scans in 504 subjects. Results from the study found age-related changes in SA such that adolescence is a period in which the cortex is greatly expanding and reaches the maximum individual peak in SA during this time. Further, the same study found that those with the highest IQ had the greatest rate of cortical SA change during this period. [@bib0285] found a significant relationship between age with gyral and sulcal shape in a sample of 148 participants aged 18--82. A more recent two-year longitudinal study with 52 participants found overall decreases in gyrification index in youth who were between the ages of 11 and 17 at baseline, with significant widening of sulci and loss of SA within the frontal cortex ([@bib0005]). Other samples have found reduced PFC surface complexity in teens compared to children ([@bib0410]), and reduced PFC gyrification in young adults compared to early teens ([@bib0225]). Further, increased gyrification has been associated with enhanced vocabulary knowledge in typically developing youth ([@bib0470]). In a large cohort of 322 healthy adults spanning ages 20--85, SA decreases were most robust within the dorsomedial frontal, and PFC gyrification decreases were observed with older age ([@bib0195]). Sex differences in folding have also been noted with females demonstrating greater gyrification in PFC compared to males ([@bib0275], [@bib0340]). Lastly, a large longitudinal study in 647 participants found an inverted-U shaped trajectory of SA maturation between the ages of 3 and 30 ([@bib0355]). Changes in SA appeared to peak later than cortical thickness in the large cohort. The same study found that gyrification index (*note*: this index differs from the [@bib0380] LGI measure) and convex hull area influence SA changes during early to late adolescents; however, late adolescent changes in SA may be most attributed by reductions in gyrification in comparison to reduced convex hull area. Further, SA may peak at later developmental periods compared to other cortical measures such as volume ([@bib0490]). Preliminary evidence suggests that later developing regions, such as the PFC ([@bib0130]), continue to undergo gyrification, cortical surface shape, and SA changes during adolescents and young adulthood.

While several studies have demonstrated a great degree of genetic influences on cortical thickness, gray, and white matter volume (see [@bib0100]), studies of gyrification or surface characteristics among small samples of monozygotic (MZ) twins demonstrate observable differences ([@bib0020], [@bib0045], [@bib0325], [@bib0480]), suggesting that environmental factors may influence the shape of the cortical surface (see [@bib0485]) especially in secondary and tertiary sulci ([@bib0250]). For example, [@bib0180] found that PFC gyrification was no more similar in MZ twins compared to dizygotic twins. Therefore, compared to other brain characteristics, such as gray and white matter volume, surface morphometry values (including gyrification) appear to be significantly influenced by environmental factors compared to genetics, although this needs to be confirmed in larger sample sizes.

Therefore, gyrification may reflect changes sensitive to repeated behavioral or environmental influences, such as substance use, although additional research in emerging adults is needed. To our knowledge, only one study has examined surface morphology in a sample of young cannabis users ([@bib0295]). [@bib0295] examined sulcal concavity, a measure similar yet distinct from a 3-dimensional gyrification value. The study noted decreased sulcal concavity in the left PFC and bilateral temporal lobes of young adult cannabis users compared to controls ([@bib0295]). The study also failed to find any significant differences in global SA after controlling for potential confounds, suggesting a unique characteristic of sulcal curvature differences in regions undergoing neuromaturation in young cannabis users ([@bib0295]). The same study did not examine sub-regional differences in SA or how sulcal differences between cannabis users and non-users relate to downstream behavioral phenotypes, such as neuropsychological function.

Because cannabis use has an age of onset (SAMHSA, 2014) that overlaps with continued PFC gyrification development ([@bib0410], [@bib0225]), examining the impact of cannabis use on gyrification remains an important area to investigate. The current study examined whether cannabis use status predicted PFC or parietal gyrification in a sample of adolescents and emerging adults. Surface morphology may be related to cortical thickness and volume ([@bib0005]). Given that both reductions in cortical thickness and volume ([@bib0265], [@bib0350]) and reductions in PFC sulcal concavity ([@bib0295]) were previously found in young cannabis users, we predicted that cannabis users would demonstrate reduced gyrification and SA in PFC and parietal regions. Reduced SA and gyrification may be most pronounced in both inferior frontal and parietal regions that show reductions in volume ([@bib0075], [@bib0350]) Within regions that differed between cannabis users and controls, follow-up analyses examined brain--behavior relationships in both groups.

2. Materials and methods {#sec0010}
========================

2.1. Participants {#sec0015}
-----------------

Participants included 68 (33 cannabis-users, 35 controls) right-handed adolescents and emerging adults between the ages of 18--25 (21 male and 12 female cannabis-users; 15 male and 20 female controls) from a larger imaging genetics study (PI: Lisdahl, NIH R03 DA027457). Exclusion criteria included MRI contraindications; history of chronic medical or neurologic illness or injury (meningitis, HIV, epilepsy, brain tumor, traumatic brain injury, \>2 min of unconsciousness and concussion symptoms, stroke, cerebral palsy, Parkinson\'s disease, Huntington\'s disease, high blood pressure, diabetes, chronic migraines); history of a learning disability; complications during birth/premature birth; prenatal exposure to alcohol (\>4 drinks/day or \>7 drinks/week) or illicit drugs (\>10 uses); current use of psychoactive medication; preexisting DSM-IV Axis I disorders independent of substance use; current pregnancy; \>20 lifetime use occasions of any of the following drug categories (stimulants, ecstasy, inhalants, hallucinogens, sedatives, or opiates); and refusal to remain abstinent from all drugs and alcohol for at least seven days. Individuals that classified as very heavy alcohol drinkers (\>8 standard drinks per week on average) were also excluded. Eligible participants consisted of two groups, cannabis users (\>25 past year and \>50 lifetime joints) and controls (≤5 past year and \<15 lifetime joints). Groups were matched as closely as possible on age, education, ethnicity, gender, and verbal IQ.

2.2. Procedures {#sec0020}
---------------

The Institutional Review Board at the University of Cincinnati approved all aspects of this study. Participants were recruited through advertisements in a local free newspaper and fliers. Those interested were screened by phone for exclusionary criteria, which have been described in further detail elsewhere (see [@bib0350]; [@bib0245]). Briefly, a semi-structured interview based on DSM-IV-TR criteria for Axis I psychotic, anxiety, and mood disorders was administered (see [@bib0125]). Next, eligible participants completed either one or two sessions. Those with moderate or greater substance use completed the questionnaires, drug use interview, neuropsychological battery, and MRI scan in two sessions (typically 2--3 days apart; see biological samples below). Participants were paid \$160 for two sessions (5.5 h) (\$110 for one, 3.5 h) and received parking reimbursement, local substance treatment resources and images of their brain.

2.3. Screening inventories and questionnaires {#sec0025}
---------------------------------------------

### 2.3.1. Demographic information {#sec0030}

Participants completed a Background Questionnaire outlining demographic variables (see [Table 1](#tbl0005){ref-type="table"}).Table 1Demographic, substance use information according to group.Cannabis users\
(*n* = 33)\
*M* (SD) \[range\]Controls\
(*n* = 35)\
*M* (SD) \[range\]Age21.21 (2.34)\
\[18--25\]21.14 (2.33)\
\[18--25\]% Female36.4%57.1%% Caucasian66.7%65.7%WRAT-4 Reading\
Standard Score103.36 (15.86)\
\[73--134\]101.37 (10.13)\
\[81--120\]Education13.12 (1.75)\
\[9--17\]13.91 (1.72)\
\[11--18\]Beck Depression\
Inventory Total-2\*5.12 (3.84)\
\[0--17\]3.31 (3.39)\*\
\[0--14\]Past year nicotine use\*\*1788.67 (2532.57)\
\[0--7350\]455.86 (1093.0)\
\[0--3680\]Cotinine levels\*\*3.87 (2.39)\
\[0--6\]1.29 (2.08)\
\[0-- 6\]Past year alcohol use\*\*282.91 (382.10)\
\[0--1724\]101.8 (166.38)\
\[0--878\]Past year marijuana use\*\*548.36 (771.07)\
\[26--3895\].40 (1.22)\
\[0--5\]Past year other drug use\*\*9.82 (30.31)\
\[0--171\].11 (.53)\
\[0--3\][^2]

### 2.3.2. Biological samples {#sec0035}

Participants were administered a urine toxicology screen using the One Step Drug Screen Test, a breathalyzer test, and female participants were administered a pregnancy test. Those who tested positive for drugs and/or alcohol except cannabis and nicotine were excluded. Metabolite levels were further examined for participants that tested positive for cannabis via mass spectrometry testing. Session 2 total THC metabolite ratios, controlling for creatinine, were subtracted from session 1 total ratios to ensure there were no increases or current use while in the study (see [@bib0145]). Thus, if the difference in ratios reached \>50 ng/mL, the participant was excluded. Cotinine levels measured recent nicotine use or exposure.

### 2.3.3. Drug use {#sec0040}

Past year drug use was measured using a modified version of the Time-Line Follow-Back ([@bib0390]) interview (see [Table 1](#tbl0005){ref-type="table"} for categories). Drug use was measured by the number of standard units (cigarettes or cigars for nicotine; standard drinks for alcohol; joints for cannabis; tablets for ecstasy; grams for stimulants; number of hits or pills for inhalants, hallucinogens, and opioids; and pills or hits for sedatives). The Customary Drinking and Drug Use Record (CDDR), measured lifetime and past 3-month substance use, withdrawal symptoms, DSM-IV abuse and dependence criteria, and substance-related difficulties ([@bib0060], [@bib0405]).

### 2.3.4. Self-reported mood {#sec0045}

The Beck Depression Inventory-II ([@bib0025]) assessed current depressive symptomology.

2.4. Neuropsychological assessments {#sec0050}
-----------------------------------

### 2.4.1. Premorbid verbal intelligence/quality of education {#sec0055}

The Wide Range Achievement Test-4th edition (WRAT-4) Reading subtest ([@bib0495]) measured estimates of verbal intelligence and quality of education for group comparison purposes (see [@bib0290]).

### 2.4.2. Complex attention {#sec0060}

Complex attention was assessed using the total correct responses in the Wechsler Adult Intelligence Scale -- Third Edition (WAIS-III) Letter Number Sequencing (LNS) and the Paced Auditory Serial Attention Test (PASAT). The LNS is a subscale of the WAIS-III Working Memory Index and measures the ability to retain and manipulate bits of information over several separate trials ([@bib0475]). The PASAT is a working memory task in which participants must retain two serially presented numbers and perform a summation roughly every 2 s ([@bib0155]). LNS and PASAT total scores were used for the current study.

### 2.4.3. Cognitive inhibition {#sec0065}

The D-KEFS Color Word Interference Test Inhibition condition total completion time assessed inhibitory ability ([@bib0090]). For this task, participants were required to read the color of ink a color word is printed in (inhibition condition).

2.5. MRI data acquisition {#sec0070}
-------------------------

### 2.5.1. Parameters {#sec0075}

T1-weighted, 3-D SPGR anatomical brain scans were obtained on a 4T Varian Unity MRI scanner using a modified driven equilibrium Fourier transform (MDEFT) sequence (FOV = 25.6 cm, 256 × 256 × 192 matrix, slice thickness = 1 mm, in-plane resolution = 1 × 1 mm, TR = 13 ms, TE = 5.3 ms, flip angle = 22°). A neuroradiologist at the Center for Imaging Research reviewed anatomical scans, and participants with noted abnormalities were excluded from this sample.

2.6. MRI processing {#sec0080}
-------------------

### 2.6.1. PFC local gyrification analysis {#sec0085}

Images were preprocessed in FreeSurfer version 5.3 ([@bib0085]). Average local gyrification indices (LGI) were created using a radius set to 20 mm for each region listed below, in order to maximize sensitivity ([@bib0380], [@bib0375]), and cortical surface-based anatomical atlas ([@bib0095]). Regions of interest (ROIs) included bilateral: dorsal lateral PFC (DLPFC); medial PFC (mPFC); frontal pole; ventral medial PFC (vmPFC); ventral lateral PFC (vlPFC); and inferior parietal (infPariet). Control regions reflecting the average LGI and SA for each of the left and right hemispheres was included to test whether results were diffuse or specific to a priori defined ROIs.

### 2.6.2. Surface area analysis {#sec0090}

As part of the FreeSurfer processing stream ([@bib0085]) SA was computed for each participant. Corresponding with the ROIs listed above in the LGI analysis (see Section [2.6.1](#sec0085){ref-type="sec"}), SA was calculated for all ROIs and the hemisphere control regions.

### 2.6.3. Operating system {#sec0095}

Mac Pro with: OS X version 10.6.8, 12GB of memory, and 2×2.26 GHz Quad-Core Intel Xeon.

2.7. Statistical analyses {#sec0100}
-------------------------

All analyses were conducted using SPSS. ANOVAs, Mann--Whitney *U*-test (drug variables), and Chi-square tests were run to examine potential demographic differences as well as differences in past year drug use histories between drug groups. Variables that either significantly differed between groups or may impact neural architecture were entered as covariates ([@bib0300], [@bib0305]). Covariates included WRAT-4 Reading scaled score, age, gender, past year alcohol use, cotinine levels, and current depressive symptoms.

General linear modeling (GLM) in SPSS was used to examine whether cannabis group status was significantly associated with a priori defined LGI or SA ROIs. Standard least squares multiple regression was used; block one included covariates, and block two included cannabis group status. All dependent variables were normally distributed and there was no evidence of multicollinearity. Significance was determined if *p* \< .05, and correction for multiple comparisons was calculated for each hemisphere\'s results utilizing Benjamini and Hochberg\'s False Discovery Rate correction (FDR; [@bib0035]). All FDR corrections were computed for the left and right hemispheres separately.

In the cannabis users, Pearson *r* correlations were run between cognitive performance (complex attention and cognitive inhibition; see [@bib0350]) and gyrification or SA ROIs that significantly differed between groups. Significance was determined if *p* \< .05 (after FDR correction).

3. Results {#sec0105}
==========

3.1. Demographic and mood information {#sec0110}
-------------------------------------

### 3.1.1. Demographic and self-report variables {#sec0115}

ANOVAs and Chi-squares were run to test differences between cannabis users and controls. There were significant differences in self-reported BDI-II depressive symptoms, with cannabis users reporting on average 2 more symptoms than controls, but still within the minimal range of symptoms \[*F*(1,66) = 4.24, *p* = .04\]. Groups did not differ in ethnicity \[22 Caucasian cannabis users and 23 Caucasian controls \[*X*^2^(4) = 3.86, *p* = .43\], gender \[*X*^2^(1) = 2.9, *p* = .09\], past year Cahalan alcohol drinking patterns criteria \[*X*^2^(5) = 4.3, *p* = .51\], age \[*F*(1,66) = .02, *p* = .90\], WRAT-4 Reading standard score \[*F*(1,66) = .39, *p* = .54\], education \[*F*(1,66) = 3.6, *p* = .06\], annual income \[*F*(1,66) = .17, *p* = .68\], or body mass index \[*F*(1,65) = .46, *p* = .50\].

### 3.1.2. Drug variables {#sec0120}

Mann--Whitney *U* tests revealed significant differences between cannabis users and controls in past year nicotine (*U* = 244.5, *p* \< .01), recent nicotine use (*U* = 199.5, *p* ≤ .01), past year alcohol use (*U* = 334.5, *p* = .003), past year cannabis use (*U* = 0.00, *p* ≤ .01), and past year other drug use (measured as standardized hits or pills of stimulants, ecstasy, inhalants, hallucinogens, sedatives and opiates; *U* = 236, *p* ≤ .01). The cannabis group used more of these substances in comparison to controls, although the other drug use category was relatively low for the vast majority of the cannabis users and our exclusion criteria consistent with ≤ 20 lifetime uses of any drug category.

3.2. Gyrification results {#sec0125}
-------------------------

### 3.2.1. Cannabis group {#sec0130}

After controlling for WRAT-4 Reading scaled score, age, gender, past year alcohol use, cotinine levels, and current depressive symptoms, cannabis users demonstrated significantly reduced gyrification in bilateral medial PFC (Right: \[*t*(59) = −2.9, *beta* = −.41, *p* = .005; FDR corrected *p* = .02\] and Left: \[*t*(59) = −3.1, *beta* = −.45, *p* = .003; FDR corrected *p* = .02\]); bilateral frontal poles (Right: \[*t*(59) = −2.7, *beta* = −.38, *p* = .009; FDR corrected *p* = .02\] and Left: \[*t*(59) = −3.1, *beta* = −.46, *p* = .003; FDR corrected *p* = .02\]); and bilateral ventral-medial PFC (Right: \[*t*(59) = −2.8, *beta* = −.40, *p* = .006; FDR corrected *p* = .02\] and Left: \[*t*(59) = −3.0, *beta* = −.44, *p* = .004; FDR corrected *p* = .02\]) (see [Fig. 1](#fig0005){ref-type="fig"}).Fig. 1ROI\'s of cannabis users with significantly reduced LGI and the corresponding *p* values and FDR corrected p values corrected for multiple comparisons. *Note*: yellow = medical PFC; blue = frontal pole; orange = ventral medial PFC; Lh = left hemisphere; Rh = right hemisphere; LGI = local gyrification index.

No significant group differences were observed in LGI for total hemisphere (control region) (Right: \[*t*(58) = −1.6, *beta* = −.25, *p* = .11\] and Left: \[*t*(58) = −.62, *beta* = −.09, *p* = .54\]); dorsolateral PFC (Right: \[*t*(59) = .05, *beta* = .007, *p* = .96\] and Left: \[*t*(59) = 1.5, *beta* = .2, *p* = .15\]); ventral lateral PFC (Right: \[*t*(59) = −1.5, *beta* = −.23, *p* = .13\] and Left: \[*t*(59) = −.7, *beta* = −.11, *p* = .49\]); or bilateral inferior parietal cortex (Right: \[*t*(60) = −1.9, *beta* = −.28, *p* = .06\] and Left \[*t*(60) = −.41, *beta* = −.06, *p* = .69\]). There were no regions where cannabis users showed significant increases compared to controls.

3.3. Surface area results {#sec0135}
-------------------------

### 3.3.1. Cannabis group {#sec0140}

After controlling for WRAT-4 Reading scaled score, age, gender, past year alcohol use, cotinine levels, and current depressive symptoms, cannabis users demonstrated significantly reduced SA in the left ventral medial \[*t*(60) = −2.5, *beta* = −.35, *p* = .02; FDR corrected *p* = .09\], and left ventral lateral PFC \[*t*(60) = −2.7, *beta* = −.32, *p* = .008; FDR corrected *p* = .09\], although these findings were only marginally significant after correcting for multiple comparisons. No significant group differences were observed in total hemisphere (control region) SA (Right: \[*t*(59) = −1.1, *beta* = −.12, *p* = .26\] and Left: \[*t*(59) = −1.9, *beta* = −.2, *p* = .07\]); bilateral medial PFC (Right: \[*t*(60) = −1.0, *beta* = −.12, *p* = .30\] and Left: \[*t*(60) = −1.8, *beta* = −.22, *p* = .08\]); bilateral dorsolateral PFC (Right: \[*t*(60) = −.65, *beta* = −.07, *p* = .52\] and Left: \[*t*(60) = −1.7, *beta* = −.19, *p* = .10\]); right ventral medial PFC \[*t*(60) = −1.5, *beta* = −.21, *p* = .14\]; right ventral lateral PFC \[*t*(60) = −1.4, *beta* = −.16, *p* = .18\]; or bilateral inferior parietal (Right: \[*t*(60) = −1.3, *beta* = −.15, *p* = .20\] and Left: \[*t*(60) = −.53, *beta* = −.07, *p* = .60\]).

3.4. Brain--behavior results {#sec0145}
----------------------------

### 3.4.1. Cannabis group {#sec0150}

Positive correlations were found between increased gyrification and improved LNS performance in the right medial PFC \[*r* = .50, *n* = 33, *p* = .003\], right ventral medial PFC \[*r* = .38, *n* = 33, *p* = .03\] and right frontal pole \[*r* = .46, *n* = 33, *p* = .007\].

### 3.4.2. Controls {#sec0155}

No significant correlations were observed between brain regions that significantly differed between groups and neuropsychological performance in controls.

4. Discussion {#sec0160}
=============

This study examined whether cannabis use status predicted prefrontal or parietal local gyrification index (LGI) and surface area (SA) in a sample of otherwise healthy adolescents and emerging adults. Consistent with the predicted hypotheses, after controlling for reading ability, age, gender, past year alcohol use, cotinine levels, and current depressive symptoms, cannabis users had reduced LGI in bilateral medial frontal, ventral medial, and frontal poles. No significant differences were found in hemispheric or inferior parietal LGI, suggesting that aberrant gyrification may be localized to particular PFC regions in emerging adults. Further, group differences in SA in orbitofrontal areas were consistent with LGI findings, but did not pass correction for multiple comparisons.

Decreased gyrification in right medial, ventral medial, and frontal pole regions, were associated with poorer performance on complex attention in cannabis users, suggesting that reduced gyrification confers a functional deficit. This is consistent with previous studies suggesting increased gyrification is associated with better cognitive functioning ([@bib0470]) and may reflect improved cognitive control ([@bib0270]).

Present findings are consistent with prior research demonstrating unique PFC surface morphology characteristics in cannabis using youth ([@bib0295]). Specifically, [@bib0295] found reduced sulcal concavity in the PFC of cannabis users in comparison to non-users and failed to find global hemispheric differences in SA. In the current study we found significantly reduced LGI in medial, ventral medial, and frontal poles in cannabis users compared to controls. We found no significant differences in inferior parietal LGI and marginal differences in SA, while in an overlapping sample we previously reported subtle volume abnormalities in this region ([@bib0350]). Though we did not examine the relationship between either LGI or SA and other cortical measures in this study, surface area, gyrification, and cortical thickness appear have distinct patterns in neurodevelopment from ages 6 to 22 ([@bib0355]). We also found unique patterns in cannabis effects between two cortical morphometry measures; after controlling for covariates including age and gender, results from the current study suggest that frequent cannabis use may influence LGI in a more diffuse PFC distribution compared to SA since we found only marginal reductions of SA in two PFC regions (left: ventral lateral and ventral medial PFC) among cannabis users compared to controls. Therefore, while gyrification may be partially related to gray matter volume and SA, it likely reflects a novel measure of brain maturation ([@bib0225]). Though [@bib0295] did not find global hemispheric group differences in SA, perhaps the influence of frequent cannabis use on SA is restricted to regions with later SA development. Changes in global SA during late adolescents may be primarily driven by reduced global gyrification index ([@bib0355]) and may differ from influences driving cortical thickness maturation ([@bib0490]). Future studies may want to examine how cannabis use impacts neurodevelopment utilizing multiple measures of cortical morphometry (LGI, cortical thickness, volume, and SA).

Frequent cannabis-using youth report using cannabis to cope with stressors or relax ([@bib0055], [@bib0320], [@bib0050], [@bib0210], [@bib0040]), although continued use may negatively impact regions underlying healthy affective processing ([@bib0110]). For example, the medial portions of the PFC are implicated in self-referential thought, regulation of stress response, autonomic regulation, emotional processing, and social cognition ([@bib0445], [@bib0395], [@bib0015]; for reviews see [@bib0440], [@bib0165]). Ventral medial portions of the PFC play a role in regulating amygdala activity, contextual decision-making, fear response and extinction, anticipatory responses, and social processing ([@bib0010], [@bib0260], [@bib0370], [@bib0400], [@bib0330], [@bib0335]). Animal studies suggest that the inferior frontal regions also play a vital role in insight or one\'s ability to imagine consequences of behavior in new situations ([@bib0280]). The frontal pole underlies detecting contextual change, and reward-related decision-making ([@bib0345], [@bib0230]). Therefore, additional studies examining functional consequences of cannabis use in youth may focus on affective processing, reward processing, and mood symptomatology. In addition, given the potential impact of endocannabinoid signaling on PFC activation ([@bib0120]), future studies may want to examine whether genotypes related to endocannabinoid signaling interact with cannabis exposure to predict frontolimbic structural integrity in youth.

Further, there is also evidence of functional abnormalities as evidenced on fMRI studies of inhibitory control and complex working memory (see [@bib9005], [@bib9010], [@bib9020]). In an overlapping sample, our lab previously reported smaller inferior parietal volumes with small effect size among cannabis using emerging adults, although this finding did not survive multiple corrections (see [@bib0350]). Taken together, later to develop PFC regions may be more consistently susceptible to morphological abnormalities associated with cannabis use during youth.

The current study was cross-sectional; therefore, it is not possible to determine whether the LGI and SA results reflect premorbid characteristics that co-occur with the onset of cannabis use. For example, there is evidence that smaller OFC volumes and increased impulsivity predict earlier age of cannabis use onset during adolescence ([@bib0070]). However, there are no studies to date that have examined whether other cortical morphometric measures (SA or gyrification) predict the onset of cannabis use, so it is not known whether these measures are sensitive premorbid markers for addiction risk, or cannabis use potential. On the other hand, it is not known whether these morphological features are more sensitive to environmental influence later in the course of development compared to volume or cortical thickness. Therefore, larger prospective longitudinal studies are needed to examine the influence of cannabis use on multiple morphometric measures (volume, LGI, SA, cortical thickness).

There are other limitations that need to be considered. Alcohol and cannabis use among youth are highly comorbid ([@bib0215]). Although the current study excluded "very heavy" drinkers, statistically controlled for past year alcohol use, and did not find any relationship between past year alcohol use and gyrification or SA, it is possible that some of the findings are associated with combined or *simultaneous* cannabis and alcohol use. Lastly, due to the potential impact of various workstations on results ([@bib0150]) results of the current study may be specific to the particular operating system, FreeSurfer version, imaging acquisition and preprocessing. Thus, replication using different imaging parameters or processing techniques is warranted.

5. Conclusion {#sec0165}
=============

In conclusion, this study found that regular cannabis users had less complex PFC gyrification, especially in medial and ventral medial regions. Cannabis users also demonstrated marginal reductions in orbitofrontal surface area. Reduced gyrification was significantly correlated with poorer working memory. These findings may reflect alterations in synaptic connections, resulting in reduced prefrontal complexity and poorer cognitive functioning in adolescent onset cannabis users. This adds to converging lines of evidence that suggest that adolescence and emerging adulthood is a sensitive period for drug-induced neurocognitive effects. Understanding the impact of regular cannabis use on neurodevelopment during adolescence and emerging adulthood remains a significant public health priority and additional prospective longitudinal studies are warranted.
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